Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Lea Hoisnard"'
Publikováno v:
RMD Open, Vol 10, Iss 1 (2024)
Objectives Biosimilar-originator equivalence has been demonstrated in phase 3 trials in a few indications of infliximab, etanercept and adalimumab. The objective of our study was to compare the persistence and safety of biosimilars versus originators
Externí odkaz:
https://doaj.org/article/200e5cba374e4e0497b4f586ed5603a2
Publikováno v:
RMD Open, Vol 8, Iss 2 (2022)
Introduction Tumour necrosis factor inhibitor (TNFi) agents are most often the first-choice biological treatment for patients with psoriatic arthritis (PsA). When their discontinuation is needed, a switch to another TNFi or to another therapeutic cla
Externí odkaz:
https://doaj.org/article/41fc3a56585b4511a4df1e396eb522ab
Autor:
Lea Hoisnard, Laura Pina Vegas, Rosemay Dray-Spira, Alain Weill, Mahmoud Zureik, Emilie Sbidian
Publikováno v:
Annals of the Rheumatic Diseases. 82:182-188
ObjectivesTo assess the risk of major adverse cardiovascular events (MACEs) and venous thromboembolism events (VTEs) among patients initiating a Janus kinase inhibitor (JAKi) (tofacitinib and baricitinib) versus adalimumab in a large real-world popul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86e0b5d1db890a032ca109de7ba1a86f
https://doi.org/10.1136/ard-2022-222824
https://doi.org/10.1136/ard-2022-222824
Autor:
Lea Hoisnard, Pr Sébastien Maury, Pr Matthieu Mahévas, Khalil El Karoui, Lydia Roy, José L. Cohen, Pr Aurélien Amiot, Pr Pascal Claudepierre, Pr Philippe Grimbert, Pr Emilie Sbidian
Publikováno v:
Journal of the American Academy of Dermatology. 87:AB137
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1fc38e9a4ebe2dd14575fc27f68c1bc
https://doi.org/10.1016/j.jaad.2022.06.579
https://doi.org/10.1016/j.jaad.2022.06.579
Autor:
Pierre Nguyen, Noémie Roland, Anke Neumann, Léa Hoisnard, Thibault Passeri, Lise Duranteau, Joël Coste, Sébastien Froelich, Mahmoud Zureik, Alain Weill
Publikováno v:
The Lancet Regional Health. Europe, Vol 42, Iss , Pp 100928- (2024)
Summary: Background: Nomegestrol acetate (NOMAC) is a synthetic potent progestogen. This study aimed to assess the risk of intracranial meningioma associated with the prolonged use of NOMAC. Methods: Observational cohort study using SNDS data (France
Externí odkaz:
https://doaj.org/article/4de56d3b281447f18d30a30f74117619
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract TNF-alpha inhibitors have revolutionized the therapeutic care in chronic inflammatory diseases. Several biosimilar products were commercialized at their patent expiry, substantially decreasing the cost of treatment. This longitudinal descrip
Externí odkaz:
https://doaj.org/article/597d7c77fc044ea9847b7f7c49cc5be2
Autor:
Léa Hoisnard, Bénédicte Lebrun-Vignes, Sébastien Maury, Matthieu Mahevas, Khalil El Karoui, Lydia Roy, Anissa Zarour, Marc Michel, José L. Cohen, Aurélien Amiot, Pascal Claudepierre, Pierre Wolkenstein, Philippe Grimbert, Emilie Sbidian
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract Increasing number of Janus kinase (JAK) inhibitors have been approved for chronic haematopoietic neoplasms and inflammatory/autoimmune diseases. We aimed to assess safety of the first three approved JAK inhibitors: ruxolitinib, tofacitinib a
Externí odkaz:
https://doaj.org/article/2ca98a65657442a48f5704f32414808b